CDR-Life Inc.’s Post

Thanks IQVIA Institute for Human Data Science for shedding light on these significant innovations! Witnessing the remarkable progress in lung cancer treatment is truly motivating, paving the way for better care and outcomes. These advancements stand as a testament to our commitment to revolutionize the healthcare pathway. In this dynamic landscape, AI emerges as a game-changer, amplifying the scope of personalized treatment. We're charting a path toward a future where innovative treatments redefine hope for patients fighting lung cancer. These developments mark a promising era, empowering us to embrace the potential of these innovative therapies to anticipate the breakthroughs of tomorrow.

Neoantigens have been sparking our imagination for a while now, with several companies pursuing neoantigen-based cancer vaccines. Imagine taking this a step further and developing personalized T-cell-based cancer therapies, with targeting precision unmatched by any "common" tumor antigen target... And yet, as the authors write, the best path may lay in the middle, and leveraging both neoantigen-specific and shared-antigen-specific T cells may lead to the best outcomes: "A more comprehensive therapeutic strategy aimed at (1) targeting both neoantigen-specific and shared-antigen-specific T cells; and (2) boosting pre-existing responses as well as generating de novo response seems to be the approach that comes with the highest chances of broad success." Nice succinct yet informative review.

Cancer is a formidable disease to cure. The complexity and adaptability of cancer cells, combined with the challenges in early detection and treatment side effects mean researchers must cast a wide net to find effective and safe therapies.  New clinical trials featured on our blog are evaluating two different types of medications that target cancer cells in different ways, while sparing healthy cells. One study is designed to treat epithelial ovarian cancer and the other is for people with advanced breast cancer. Learn how these studies differ and why they are important contributions to the ongoing effort to cure cancer: https://lnkd.in/g3wemy5v. #FINISHCANCER #clinicaltrials #ovariancancer #breastcancer

CDK4/6 inhibitor resistant ER+ HER2- breast cancer is universally lethal and new treatments are desperately needed. In the attached paper in Molecular Cancer Therapeutics from my old Baylor laboratory, together with Charles Foulds laboratory, we identified a new treatment hypothesis. The Wee1 family kinase PKMYT1 was found to be estrogen-regulated in endocrine therapy (ET) sensitive breast cancer cells, but constitutive in tumors that developed ET resistance. In clinical samples, high PKMYT1 mRNA levels associated with resistance to both ET and CDK4/6 inhibition. The PKMYT1 inhibitor lunresertib (RP-6306) with gemcitabine selectively and synergistically reduced the viability of ET and palbociclib-resistant ER+ breast cancer cells without functional p53. In vitro, the combination increased DNA damage and apoptosis. In palbociclib-resistant, TP53 mutant PDX organoids and xenografts, RP-6306 with low-dose gemcitabine induced greater tumor volume reduction compared to treatment with either single agent. In supplementary data, sensitivity to the more commonly used drug in this setting 5FU (i.e. capecitabine) was similarly increased by exposure to RP-6306 (Figure S13). The Baylor team is looking forward to seeing these findings being translated into ER+ ET and CDK4/6 resistant breast cancer clinical trials soon! https://lnkd.in/g4wWvkwA

In early-stage cancer patients, a large portion of elevated cell-free DNA (cfDNA) originates from non-tumor sources, with the increase in cfDNA levels varying by cancer type and potentially linked to the liver's clearance efficiency. "...a large majority of cfDNA in cancer patients originates from non-tumor sources, and that the presence of early-stage cancer results in a multiplicative increase in the concentration of cfDNA originating from healthy tissue. The magnitude of the multiplicative increase is cancer-type specific and ranges from a ~1.3-fold increase in lung cancer, to a ∼12-fold increase in patients with liver cancer." #liquidbiopsy #oncology #ctdna #cfdna #biomarkers https://lnkd.in/g7pNbS8Q

Unprecedented Outcomes: 5-Year Follow-up of Lorlatinib Treated Patients with Advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK-positive NSCLC. A post hoc analysis of the phase III CROWN study evaluated long-term outcomes of lorlatinib versus crizotinib in patients with previously untreated, advanced, ALK-positive non–small cell lung cancer. After 5 years of follow-up, the longest progression-free survival (PFS) ever was reported with any single-agent molecular targeted treatment not only in advanced NSCLC but across all metastatic solid tumors. These findings set a new benchmark for targeted therapies in cancer. Solomon BJ, Liu G, Felip E, Mok, SKM et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Onc. 2024. Open Access. Presented in part at the ASCO annual meeting, Chicago, IL, May 31, 2024 https://lnkd.in/eXNnRcxy

Colon cancer is the leading cause of cancer death in men under 50 and the second leading in women – but when detected early, 9 in 10 of these deaths are preventable. 1,2 This Colon Cancer Awareness Month, we’re proud to partner with Polymedco, the makers of OC-Auto FIT, a noninvasive screening solution that can detect early warning signs so more people can get treatment before it’s too late. Together, we are promoting the importance of early, annual screening. Follow Polymedco to learn more about their mission of saving more lives through early detection. 1.Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820 2. Tepus M, Yau TO. Non-invasive colorectal cancer screening: an overview. 2020;7(3):62-73. doi:10.1159/000507701Gastrointest Tumors.

Cachexia, a severe muscle wasting condition, presents a significant obstacle in cancer treatment, especially in cases of pancreatic cancer. A recent study led by Liu et al. unveils how pancreatic cancer expedites cachexia by manipulating immune cells called macrophages. These macrophages release TWEAK, a substance that exacerbates muscle loss. Moreover, the research highlights the crucial roles of CCL5 and CCL2 in promoting cachexia in pancreatic cancer by facilitating TWEAK activation.These findings provide promising insights into potential treatments to prevent cachexia in cancer patients. By comprehending and disrupting the underlying mechanisms, one can aim to devise innovative therapeutic strategies to enhance the quality of life for individuals fighting cancer.https://https://lnkd.in/eJAWKtSe

A forum to discuss the most recent developments in oncology care: 8th Cancer World Congress 2024, Dubrovnik, Croatia https://lnkd.in/gRG9ZZWb #cancer #breastcancer #lungcancer #cancerresearch #cancerconference #cwc2024 #cancerawareness #cancercare #cancersupport #cancerprevention #CancerWorldCongress #earlybirdregistration #OncoDaily #Croatia #CancerResearch #CancerDiagnostics #CancersMDPI #MDPI #CancerNews #oncology #cancerconferences #oncologyconference #cwc2024 #prostatecancer #croatia #lungcancer #cancergenetics #coloncancer #prostatecancer #skincancer #pancreaticcancer #thyroidcancer #oralcancer #cancerworldcongress #cancerconference2024 #Oncologysymposiums #oncologymeetings #Cancerseminars #Cancertherapyevents #conferences #earlybird

ASCO: it's a wrap!!!! While I have been attending for 20+ years, 2024 marks my third ASCO with AstraZeneca, and I'm incredibly proud of the data presented, especially in lung and breast cancers! The results from ASCO, both from AstraZeneca and the broader oncology community, will significantly impact how we treat lung and breast cancer patients and improve their outcomes. As for breast cancer, while survival rates for early disease have improved dramatically over the past decades, advanced disease still has poor survival rates, with only about 30% of patients living beyond five years. We need to change this. Our goal as a community is to improve survival rates and increase the chance of a cure across all breast cancer stages and subtypes. We're working on redefining breast cancer treatment to benefit broader groups of patients. By constantly learning about breast cancer biology and pushing the boundaries of science—detecting and treating cancer earlier and finding innovative, personalized treatments—we are making progress. I am hopeful and inspired by the potential of the ASCO data to transform clinical practice and outcomes, and we may one day eliminate breast cancer as a cause of death!